# South America RNA-based Therapeutics Market

> South America RNA-Based Therapeutics Market Research Report By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Application (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations), By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.1%
- **2024:** $ 1,465.3 Million
- **2025:** $ 1,554.68 Million
- **2035:** $ 2,811.1 Million
- **Key Players:** Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US)

**Report ID:** MRFR/HC/50895-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-rna-based-therapeutics-market-52654

---

## Market Summary

## **South America RNA-Based Therapeutics Market Overview**

As per MRFR analysis, the South America RNA-Based Therapeutics Market Size was estimated at 770 (USD Million) in 2023. The South America RNA-Based Therapeutics Market Industry is expected to grow from 849 (USD Million) in 2024 to 2,500 (USD Million) by 2035. The South America RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 10.316% during the forecast period (2025 - 2035).

## **Key South America RNA-Based Therapeutics Market Trends Highlighted**

The South America RNA-Based Therapeutics Market is witnessing notable trends driven by several factors. One significant market driver is the increasing prevalence of genetic disorders and chronic diseases in the region, which has heightened the demand for innovative treatment solutions. Many South American countries are enhancing their healthcare infrastructures and investing in biotechnology research, fostering an environment conducive to the growth of RNA-based therapies.

Government initiatives aimed at supporting biotech companies through funding and regulatory reforms are also key contributors to the expansion of this market. Opportunities in the South American RNA-Based Therapeutics Market include collaborations between local research institutions and international pharmaceutical companies. Such partnerships can facilitate knowledge transfer and accelerate the development of new RNA-based therapies tailored to the unique genetic profiles found in South American populations.

Furthermore, there is significant potential for the application of RNA technology in vaccine development, especially given the recent global focus on infectious diseases and pandemics, with many countries in the region adapting their public health strategies accordingly. Recent trends also reflect a growing interest in personalized medicine, which is becoming increasingly important in South America. Advancements in genomics and biotechnology are paving the way for targeted therapies that address the specific needs of individual patients.

Moreover, as governments prioritize healthcare investments, there is an emerging emphasis on regulatory flexibility to expedite the approval of innovative therapies, which is crucial for meeting the health challenges faced by the region. This combination of supportive government policies, collaborations, and a focus on personalized medicine is shaping a dynamic landscape for RNA-based therapeutics in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America RNA-Based Therapeutics Market Drivers**

### **Rising Incidence of Genetic Disorders**

In South America, the incidence of genetic disorders is increasing, leading to a higher demand for RNA-based therapeutics which can target these conditions effectively. According to the Pan American Health Organization, genetic disorders affect over 1 in 1,000 live births in the region, indicating a significant patient base needing advanced therapies. Organizations like the Brazilian Society of Medical Genetics are actively working to raise awareness and promote Research and Development (R&D) in this sector.

This increased incidence of genetic disorders creates substantial growth opportunities for the South America RNA-Based Therapeutics Market Industry as more patients seek innovative treatment options.

### **Government Support and Funding**

Governments across South America are increasingly investing in bio-pharmaceuticals and RNA-based therapeutics as part of their health care initiatives. The National Health Ministry of Argentina announced a significant increase in funding for biotechnology projects, promoting innovation in therapeutics. This governmental backing fosters an environment conducive for Research and Development (R&D) and encourages private investments, boosting the South America RNA-Based Therapeutics Market Industry.

With an estimated 20% increase in government allocations for health research, the support translates into more resources and programs aimed at enhancing therapeutic effectiveness and accessibility in the region.

### **Growing Collaborations in Research**

The advancement of RNA-based therapies is being expedited by partnerships between pharmaceutical companies and academic institutions in South America. The University of São Paulo has formed partnerships with private companies to improve its research and development (R&D) initiatives that concentrate on mRNA technologies. According to a report from the Brazilian Association of Pharmaceutical Research, the number of such collaborations has increased by more than 30% in the past three years, indicating a strong interest in innovation in the RNA therapeutic market.

These partnerships are essential for the advancement of the South American RNA-Based Therapeutics Market Industry, which in turn provides improved treatment options for a variety of diseases.

## **South America RNA-Based Therapeutics Market Segment Insights**

### **RNA-Based Therapeutics Market Technology Insights**

The South America RNA-Based Therapeutics Market has shown substantial growth, particularly within the Technology segment, which encompasses innovative areas such as RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology. RNA Interference is vital for its ability to silence specific genes involved in various diseases, thus offering targeted therapies with reduced side effects, which is particularly significant in managing complex conditions like cancer and genetic disorders.

Conversely, Antisense Oligonucleotides provide robust tools for modulating gene expression, with a focus on treating rare and chronic diseases, showcasing the segment's capacity to address unmet medical needs across the region. mRNA Therapeutics has gained traction with the rising acceptance of mRNA technology exemplified during the recent health crisis, proving this approach can be pivotal for rapid vaccine development and therapeutic solutions, which aligns well with the regional emphasis on improving healthcare infrastructure.

Additionally, CRISPR Technology marks a revolutionary advancement in genetic engineering, allowing for precise modifications to the genome, which opens prospects for innovative treatments in South America by tackling genetic mutations and potential hereditary diseases. The growing demand for personalized medicine and biotechnology innovations is propelling these technological segments forward, highlighting the region's strategic focus on enhancing its healthcare capabilities.

As South America looks to invest in biotechnology, these technologies not only represent significant market opportunities but also promise enhanced healthcare solutions that cater to the unique needs of the population.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **RNA-Based Therapeutics Market Application Insights**

The Application segment of the South America RNA-Based Therapeutics Market showcases significant opportunities and growth potential, driven by increasing rates of oncological and infectious diseases in the region. Oncology, in particular, plays a critical role within this segment due to the rising prevalence of cancer, prompting a surge in innovative RNA-based therapies aimed at improving treatment outcomes. Infectious diseases also present a pressing healthcare challenge in South America, where RNA therapeutics offer novel solutions for tackling urgent public health concerns, including viral outbreaks and bacterial infections.

Genetic disorders are gaining attention, with RNA therapeutics offering hope for effective treatments through gene silencing and editing technologies. Meanwhile, the cardiovascular diseases sector remains pivotal, as research focuses on RNA modalities that can improve heart health and reduce systemic risks. Collectively, these applications are poised to address significant health issues in the region, offering therapeutic advancements that align with the urgent healthcare needs and market dynamics of South America.

As these therapeutic modalities evolve, they have the potential to reshape the healthcare landscape while contributing to the overall growth of the South America RNA-Based Therapeutics Market.

### **RNA-Based Therapeutics Market End Use Insights**

The South America RNA-Based Therapeutics Market is witnessing significant growth driven by its end use across various domains, notably Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. Pharmaceutical Companies play a critical role as they leverage RNA-based therapies to innovate and develop novel medicines, reflecting a growing trend in precision medicine and targeted treatments. Research Institutions are also pivotal, focusing on cutting-edge studies that explore the potential of RNA therapies in treating various diseases, thereby fueling advancements in the market.

Moreover, Contract Research Organizations have emerged as key players, providing essential support to pharmaceutical companies and institutions in the form of specialized services, clinical trials, and R&D expertise. The interplay among these players results in a dynamic ecosystem that fosters rapid advancements and enhances the overall landscape of RNA-based therapeutics in South America. This synergy not only aids in efficient product development but also opens avenues for collaboration and funding, enhancing the market's resilience and adaptability in response to evolving healthcare needs.

Overall, the diverse end use applications underline the importance of RNA-based therapeutics in revolutionizing treatment paradigms and responding to the unmet medical needs in the region.

### **RNA-Based Therapeutics Market Delivery Method Insights**

The Delivery Method segment of the South America RNA-Based Therapeutics Market is increasingly gaining attention due to its pivotal role in the effective administration of RNA-based therapeutics. Various techniques are explored within this segment, such as Liposomes, which are recognized for their ability to encapsulate and deliver RNA molecules efficiently, enhancing the stability and bioavailability of therapeutics. Nanoparticles are another critical technology, favored for their versatility and capability to target specific cells, thereby minimizing off-target effects.

Viral Vectors dominate the landscape as they are naturally adept at delivering genetic material into cells, making them significant for therapeutic applications. Electroporation also plays a pivotal role, allowing for the efficient introduction of RNA into cells through electrical pulses, promoting the uptake of therapeutics. The growing focus on precision medicine and personalized therapies is propelling innovation within these delivery methods, addressing the unique health needs of diverse populations in South America. Overall, the advancements in this segment are expected to drive substantial growth and enhance treatment outcomes across various indications in the region.

### **RNA-Based Therapeutics Market Regional Insights**

The South America RNA-Based Therapeutics Market is experiencing notable growth across its regional segmentation, prominently featuring Brazil, Mexico, Argentina, and the Rest of South America. Brazil stands out as a leading market, driven by its robust healthcare infrastructure, increasing investments in Research and Development, and a growing focus on innovative therapeutics. Mexico is also emerging, characterized by a burgeoning biotech sector and supportive government policies aimed at enhancing health outcomes through advanced treatments.

Argentina demonstrates significant potential due to its skilled workforce and emphasis on local bio-pharmaceutical production, which fosters a strong research environment. Meanwhile, the Rest of South America contributes substantially through diverse regional initiatives that encourage the adoption of RNA-based therapies. Overall, this regional expansion is fueled by increasing healthcare demands, technological advancements, and a growing recognition of RNA-based therapeutics' potential to treat various diseases, enriching the South America RNA-Based Therapeutics Market data and statistics.

As stakeholders continue to invest in this sector, opportunities for innovation and collaboration abound, paving the way for future market growth.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America RNA-Based Therapeutics Market Key Players and Competitive Insights**

The South America RNA-Based Therapeutics Market has gained significant traction over the past few years, attracting notable interest from both established and emerging players. This burgeoning market is characterized by rapid advancements in biotechnology, the growing prevalence of chronic diseases, and a shifting landscape towards personalized medicine. Companies are focusing on developing innovative RNA-based solutions, generating fierce competition that drives investments in research and development.

The rise in collaborations between academic institutions and pharmaceutical companies is also fostering a robust ecosystem conducive to the growth of RNA therapeutics. As a result, stakeholders are keenly assessing market trends, regulatory frameworks, and competitive strategies to enhance their positions and capitalize on the forecasted growth opportunities in the region.

In the South America RNA-Based Therapeutics Market, CureVac commands a notable presence with its innovative mRNA technology platform. The company is well-regarded for its commitment to developing transformative therapies that address unmet medical needs. CureVac leverages its strengths in clinical research and development, showcasing a robust pipeline of products targeting a variety of diseases, including cancer and infectious diseases. The firm has been proactive in establishing strategic partnerships and collaborations with local research entities, which have not only bolstered its market position but also enhanced its capabilities in navigating regulatory environments across South America.

This agile approach, combined with a focus on delivering high-quality RNA therapeutics, underlines CureVac's potential for continued growth in the region. BioNTech has also gained significant recognition in the South America RNA-Based Therapeutics Market, primarily due to its pioneering work in mRNA-based vaccines and therapies. The company has positioned itself as a leader by launching key products aimed at various therapeutic areas, which has resonated well in the region. BioNTech's strengths lie in its innovative research framework, extensive intellectual property, and partnerships with local organizations that facilitate development and distribution.

Recent mergers and acquisitions have further expanded its reach and capabilities, enhancing its service offerings like customized cancer immunotherapies tailored for specific patient needs. By investing in local manufacturing capabilities and engaging in collaborative initiatives, BioNTech is well-placed to strengthen its competitive edge and deliver impactful RNA-based solutions to the South American market.

### **Key Companies in the South America RNA-Based Therapeutics Market Include**

## **South America RNA-Based Therapeutics Market Industry Developments**

The South America RNA-Based Therapeutics Market has recently seen significant developments, particularly with key companies like Moderna, BioNTech, and CureVac leading advancements in mRNA technology applications. In August 2023, Moderna announced collaboration with local Brazilian firms to enhance its mRNA vaccine distribution capabilities, aiming to address health challenges in the region. Alnylam Pharmaceuticals continues to expand its presence with state-of-the-art facilities in Brazil, focusing on developing RNA interference therapies.

Notably, in June 2023, Pfizer and BioNTech solidified their partnership, targeting RNA-based treatments for malaria, with clinical trials expected to start soon. The market has witnessed a rise in valuations due to increasing investments, particularly driven by growing demand for rapid vaccine development and personalized medicine. Major happenings include Regeneron Pharmaceuticals unveiling its RNA therapeutics pipeline in November 2022, which focuses on chronic diseases prevalent in South America.

The overall growth in this sector reflects the increasing governmental support for biotechnology initiatives and collaborations across borders to facilitate Research and Development efforts in RNA technology. These trends indicate a proactive approach towards enhancing healthcare outcomes in South America through innovative RNA therapeutic solutions.

## **South America RNA-Based Therapeutics Market Segmentation Insights**

### **RNA-Based Therapeutics Market Technology Outlook**

### **RNA-Based Therapeutics Market Application Outlook**

### **RNA-Based Therapeutics Market End Use Outlook**

### **RNA-Based Therapeutics Market Delivery Method Outlook**

### **RNA-Based Therapeutics Market Regional Outlook**

## Market Drivers

### Government Support for Biotechnology

Government initiatives aimed at promoting biotechnology are significantly influencing the rna based-therapeutics market in South America. Various countries in the region are implementing policies to foster innovation and support research in biotechnology, including rna based therapies. For example, funding programs and tax incentives are being introduced to encourage private sector investment in this field. In 2025, it is estimated that government funding for biotechnology research in South America could reach upwards of $500 million, which would directly benefit the rna based-therapeutics market. This supportive environment is likely to attract both domestic and international players, further enhancing the competitive landscape and accelerating the development of new therapies.

### Advancements in Delivery Technologies

Innovations in delivery technologies are transforming the rna based-therapeutics market in South America. The development of novel delivery systems, such as lipid nanoparticles and viral vectors, enhances the efficacy and safety of rna based therapies. These advancements facilitate targeted delivery to specific tissues, thereby improving therapeutic outcomes. For instance, recent studies have shown that lipid nanoparticles can increase the bioavailability of rna molecules, potentially leading to higher success rates in clinical applications. As a result, pharmaceutical companies are likely to invest heavily in these technologies, aiming to optimize the delivery of rna based therapeutics. This focus on improving delivery mechanisms is expected to drive the growth of the rna based-therapeutics market, as more effective treatments become available to patients.

### Growing Investment in Clinical Trials

The increasing investment in clinical trials for rna based therapies is a notable driver for the rna based-therapeutics market in South America. As pharmaceutical companies recognize the potential of rna based treatments, they are allocating substantial resources to conduct clinical trials. In 2025, it is projected that the investment in clinical trials for rna based therapeutics in the region could exceed $300 million. This influx of funding is expected to facilitate the development of innovative therapies and expedite their entry into the market. Moreover, successful clinical trials can lead to regulatory approvals, further propelling the growth of the rna based-therapeutics market. The commitment to rigorous clinical research underscores the potential of rna based therapies to address critical health challenges.

### Increasing Prevalence of Genetic Disorders

The rising incidence of genetic disorders in South America is a crucial driver for the rna based-therapeutics market. As healthcare systems increasingly recognize the need for innovative treatment options, the demand for rna based therapies is expected to surge. Reports indicate that genetic disorders affect approximately 1 in 200 births in the region, leading to a growing patient population seeking effective therapies. This trend is likely to stimulate investment in research and development, as pharmaceutical companies aim to address these unmet medical needs. Furthermore, the increasing awareness among healthcare professionals and patients about the potential of rna based therapies to provide targeted treatment solutions may further enhance market growth. The rna based-therapeutics market is thus positioned to expand significantly in response to these demographic shifts.

### Rising Demand for Innovative Cancer Treatments

The escalating demand for innovative cancer treatments is driving the rna based-therapeutics market in South America. With cancer rates on the rise, there is an urgent need for effective therapies that can target cancer cells more precisely. Rna based therapeutics, particularly those utilizing RNA interference and CRISPR technology, offer promising avenues for treatment. In 2025, it is anticipated that the market for rna based cancer therapies could grow by over 25%, reflecting the increasing recognition of their potential. This trend is likely to attract significant investment from both public and private sectors, further bolstering the rna based-therapeutics market. As more patients seek advanced treatment options, the market is poised for substantial growth.

## Future Outlook

The [RNA Based Therapeutics Market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) is projected to grow at a 6.1% CAGR from 2025 to 2035, driven by advancements in gene editing, increased investment, and rising demand for personalized medicine.

**New opportunities:**

- Development of localized RNA delivery systems for targeted therapies.
- Partnerships with biotech firms for innovative RNA-based drug development.
- Expansion into telehealth platforms for RNA therapeutic consultations.

By 2035, the RNA-based therapeutics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Technology: mRNA Therapeutics (Largest) vs. CRISPR Technology (Fastest-Growing)

The distribution of market share within the technology segment of RNA-based therapeutics reveals mRNA therapeutics as the dominant force, commanding the largest share among the analyzed categories. Antisense oligonucleotides and RNA interference are also significant players, but their shares are notably smaller, occupying the fringes of the market landscape. Meanwhile, CRISPR technology is emerging as a formidable contender, with an increasing stake as interest in gene editing expands across research and clinical applications. Growth trends in this segment are primarily fueled by advancements in biotechnological research and a surge in funding directed toward innovative therapeutic solutions. The rising incidence of genetic disorders and the growing acceptance of personalized medicine are significant drivers for the expansion of RNA therapeutics. As regulatory frameworks become more favorable and technological capabilities improve, the RNA-based therapeutics technology segment is expected to witness substantial growth, particularly in CRISPR applications, which are pioneering new approaches in treatment.

Technology: mRNA Therapeutics (Dominant) vs. CRISPR Technology (Emerging)

mRNA therapeutics have established themselves as the dominant technology in the RNA-based therapeutics segment, recognized for their ability to generate robust immune responses and target various diseases effectively. On the other hand, CRISPR technology is considered an emerging powerhouse, rapidly gaining traction due to its revolutionary gene-editing capabilities. While mRNA therapeutics are primarily being utilized for vaccine development and treatment of rare diseases, CRISPR technology offers unparalleled precision in modifying genetic material. The interplay between these two technologies reflects a dynamic shift in therapeutic strategies, as CRISPR's innovative potential aligns with the growing emphasis on customizable treatments, establishing a promising future for both technologies in this evolving landscape.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

The distribution of market share among the application segments in the South America rna based-therapeutics market reveals that oncology holds the largest share, driven by a growing prevalence of cancer and advancements in targeted therapies. Infectious diseases, while smaller, are rapidly expanding due to the rising incidence of viral infections and the ongoing need for innovative therapeutics in response to emerging pathogens. Growth trends indicate that oncology will continue to dominate the space due to continuous research and development investments. In contrast, the infectious diseases segment is poised for significant growth, fueled by increased funding and initiatives aimed at combating global health threats, including pandemics. Genetic disorders and cardiovascular diseases follow but are growing at a relatively slower pace for now.

Oncology (Dominant) vs. Infectious Diseases (Emerging)

Oncology stands out as a dominant application area within the South America rna based-therapeutics market, characterized by a robust pipeline of novel therapies targeting various cancers, along with supportive regulatory frameworks. The segment benefits from strong collaborations between research institutions and pharmaceutical companies, facilitating groundbreaking innovations. Conversely, infectious diseases represent an emerging area, gaining attention due to heightened awareness and urgent need for new treatments. This segment is characterized by increased investment from governments and private sectors, driving advancements in rna-based technologies to swiftly respond to infectious disease outbreaks, ensuring improved healthcare outcomes in the region.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the end-use segment, pharmaceutical companies hold the largest share, driven by their established market presence and extensive research and development capabilities. Meanwhile, research institutions are rapidly gaining traction, representing an emerging force in the market landscape as they seek to innovate and develop new RNA-based therapeutic solutions. Contract research organizations, while significant, maintain a smaller share compared to these dominant players in the sector. The growth trends in this segment highlight a robust demand for RNA-based therapeutics across pharmaceutical companies, fueled by advancements in gene therapies and personalized medicine. Research institutions are accelerating their contributions, driven by increased funding and collaboration opportunities. Meanwhile, contract research organizations are adapting to support the growing needs of both pharmaceutical companies and research institutions, indicating a trend toward outsourcing and specialization.

Pharmaceutical Companies: Dominant vs. Research Institutions: Emerging

Pharmaceutical companies are the dominant players in the RNA-based therapeutics sector, leveraging their substantial resources and expertise to lead research and commercialization of innovative treatments. Their established infrastructure allows for efficient development and distribution of new products. In contrast, research institutions are positioned as emerging entities, contributing to groundbreaking discoveries and academic research. They serve as incubators for new ideas and technologies, often collaborating with pharmaceutical companies to translate research findings into viable therapeutic options. This collaboration enhances their standing in the market as they tap into funding for innovative projects and expand their role in the competitive landscape, driving advancements in RNA-based therapies.

### By Delivery Method: Nanoparticles (Largest) vs. Liposomes (Fastest-Growing)

The South America rna based-therapeutics market is characterized by significant market share distribution among various delivery methods. Nanoparticles hold the largest share, driven by their effectiveness in delivering therapeutic agents across biological membranes. Liposomes are gaining traction as they offer a biocompatible delivery system, capturing an increasing share of the market.

Nanoparticles (Dominant) vs. Liposomes (Emerging)

Nanoparticles are poised as the dominant delivery method due to their customizable properties and proven ability to enhance drug delivery efficiency. They allow for targeted treatment while minimizing toxicity. On the other hand, liposomes are emerging as a promising alternative, especially in specific therapeutic applications, owing to their capability to encapsulate both hydrophilic and lipophilic drugs. Their biocompatibility makes them increasingly attractive in therapeutic formulations. As innovation continues, both segments are expected to evolve, driving the growth of rna based therapeutics.

## Regional Market Share Analysis

### Brazil : Strong Growth and Innovation Hub

Brazil holds a dominant position in the South American RNA therapeutics market, accounting for approximately 45% of the total market share with a value of $650.0 million. Key growth drivers include increasing investments in biotechnology, a rising prevalence of genetic disorders, and supportive government initiatives aimed at fostering innovation in healthcare. Regulatory policies are becoming more favorable, with streamlined approval processes for RNA-based therapies, enhancing market accessibility. Additionally, Brazil's robust healthcare infrastructure supports the rapid adoption of these advanced therapeutics.

### Mexico : Growing Demand and Investment Opportunities

Mexico represents a significant portion of the South American RNA therapeutics market, with a market value of $300.0 million, accounting for about 23% of the regional share. The growth is driven by increasing healthcare expenditure, a rising incidence of chronic diseases, and a burgeoning biotechnology sector. Government initiatives are focused on enhancing research and development in RNA therapeutics, while regulatory frameworks are evolving to support faster market entry. The demand for innovative treatments is also rising among healthcare providers and patients alike.

### Argentina : Focus on Research and Development

Argentina's RNA therapeutics market is valued at $250.0 million, representing around 19% of the South American market. The growth is fueled by a strong emphasis on research and development, particularly in urban centers like Buenos Aires and Córdoba. The government is actively promoting biotechnology through funding and partnerships with academic institutions, which enhances innovation. Regulatory policies are gradually adapting to accommodate RNA therapies, although challenges remain in terms of infrastructure and investment. The local market is characterized by a mix of domestic and international players.

### Rest of South America : Varied Market Dynamics Across Regions

The Rest of South America, with a market value of $265.3 million, showcases diverse dynamics in the RNA therapeutics sector, accounting for approximately 13% of the regional market. Key growth drivers include increasing healthcare access and rising awareness of RNA therapies. Countries like Chile and Colombia are emerging as important markets, supported by government initiatives aimed at improving healthcare infrastructure. The competitive landscape features both local and international players, with a focus on addressing specific health challenges prevalent in these regions. Regulatory environments are improving, but vary significantly across countries.

## Competitive Benchmarking

The [RNA-based therapeutics market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) in South America is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and regional expansion. Key players such as Moderna (US), BioNTech (DE), and Alnylam Pharmaceuticals (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Moderna (US) focuses on leveraging its mRNA technology platform to develop a diverse pipeline of therapeutics, while BioNTech (DE) emphasizes collaborations with local biotech firms to accelerate product development and distribution. Alnylam Pharmaceuticals (US) is concentrating on advancing its RNA interference (RNAi) therapies, indicating a strong commitment to innovation in genetic medicine. Collectively, these strategies contribute to a competitive environment that is increasingly characterized by rapid technological advancements and collaborative efforts.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and establish benchmarks for quality and efficacy in RNA-based therapeutics.
In October 2025, Moderna (US) announced a strategic partnership with a leading South American pharmaceutical company to establish a local manufacturing facility. This move is expected to enhance supply chain reliability and reduce time-to-market for its mRNA therapeutics, thereby strengthening its competitive position in the region. The establishment of local manufacturing capabilities may also facilitate better access to innovative treatments for patients in South America, aligning with the growing demand for localized healthcare solutions.
In September 2025, BioNTech (DE) expanded its collaboration with a Brazilian research institution to develop RNA-based therapies targeting rare diseases. This partnership underscores BioNTech's commitment to addressing unmet medical needs in the region and highlights the importance of local expertise in the development process. By leveraging regional knowledge, BioNTech is likely to enhance its research capabilities and accelerate the delivery of novel therapeutics to the market.
In August 2025, Alnylam Pharmaceuticals (US) launched a new initiative aimed at increasing awareness and education around RNAi therapies in South America. This initiative is crucial for fostering understanding among healthcare professionals and patients, potentially leading to increased adoption of RNA-based treatments. By prioritizing education, Alnylam is positioning itself as a thought leader in the RNA therapeutics space, which may enhance its brand reputation and market share.
As of November 2025, the competitive trends in the RNA-based therapeutics market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized medicine solutions. This transition may redefine the competitive landscape, emphasizing the importance of agility and responsiveness to market demands.

## Recent News & Developments

The South America RNA-Based Therapeutics Market has recently seen significant developments, particularly with key companies like Moderna, BioNTech, and CureVac leading advancements in mRNA technology applications. In August 2023, Moderna announced collaboration with local Brazilian firms to enhance its mRNA vaccine distribution capabilities, aiming to address health challenges in the region. Alnylam Pharmaceuticals continues to expand its presence with state-of-the-art facilities in Brazil, focusing on developing RNA interference therapies.

Notably, in June 2023, Pfizer and BioNTech solidified their partnership, targeting RNA-based treatments for malaria, with clinical trials expected to start soon. The market has witnessed a rise in valuations due to increasing investments, particularly driven by growing demand for rapid vaccine development and personalized medicine. Major happenings include Regeneron Pharmaceuticals unveiling its RNA therapeutics pipeline in November 2022, which focuses on chronic diseases prevalent in South America.

The overall growth in this sector reflects the increasing governmental support for biotechnology initiatives and collaborations across borders to facilitate Research and Development efforts in RNA technology. These trends indicate a proactive approach towards enhancing healthcare outcomes in South America through innovative RNA therapeutic solutions.

## Report Scope

| MARKET SIZE 2024 | 1465.3(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1554.68(USD Million) |
| MARKET SIZE 2035 | 2811.1(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.1% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US) |
| Segments Covered | Technology, Application, End Use, Delivery Method |
| Key Market Opportunities | Advancements in RNA delivery systems enhance therapeutic efficacy in the rna based-therapeutics market. |
| Key Market Dynamics | Emerging regulatory frameworks in South America are fostering innovation in the RNA based-therapeutics market. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the current valuation of the RNA based-therapeutics market in South America?**
A: The market valuation was $1465.3 Million in 2024.

**Q: What is the projected market size for RNA based-therapeutics in South America by 2035?**
A: The projected valuation for 2035 is $2811.1 Million.

**Q: What is the expected CAGR for the RNA based-therapeutics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.1% during the forecast period.

**Q: Which technology segment is projected to have the highest valuation in the RNA based-therapeutics market?**
A: The mRNA Therapeutics segment is projected to reach $900.0 Million by 2035.

**Q: What is the estimated market size for the Oncology application in RNA based-therapeutics by 2035?**
A: The Oncology application is expected to reach $800.0 Million by 2035.

**Q: How do pharmaceutical companies contribute to the RNA based-therapeutics market in South America?**
A: Pharmaceutical Companies are projected to contribute $1690.0 Million by 2035.

**Q: What delivery method is anticipated to dominate the RNA based-therapeutics market?**
A: Viral Vectors are expected to dominate with a projected valuation of $1000.0 Million by 2035.

**Q: Which key players are leading the RNA based-therapeutics market in South America?**
A: Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, and others.

**Q: What is the estimated market size for Genetic Disorders applications in RNA based-therapeutics by 2035?**
A: The Genetic Disorders application is projected to reach $700.0 Million by 2035.

**Q: What is the expected market size for the CRISPR Technology segment by 2035?**
A: The CRISPR Technology segment is expected to reach $811.1 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-rna-based-therapeutics-market-52654*